Inflammatory bowel disease
Jul 09, 2020
Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates
Sanofi licenses NK cells of Kiadis to boost the efficacy Sanofi has licensed the natural killer (NK) cells from Kiadis Pharma for use in combination with its multiple myeloma drug Sarclisa. The deal worth of USD 986 million gives the global rights to Sanofi for therapies that could lessen an efficacy-limit...
Read More...
Feb 21, 2019
Peloton raises $150M; BiomX raises $32M; Abbott and Novo collaborate; Blaze Bioscience nets $5M
Peloton Therapeutics raises USD 150 Million for treating Advance Kidney Cancer Peloton Therapeutics has been in the process of developing small molecule drugs to treat Cancer, has raised USD 150 million. Peloton’s lead therapeutic candidate, PT2977, focuses on targeting hypoxia-inducible fac...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
